Processa Pharmaceuticals Inc (PCSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Processa Pharmaceuticals Inc (PCSA) has a cash flow conversion efficiency ratio of -1.413x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.59 Million) by net assets ($2.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Processa Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
Processa Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Processa Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Processa Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Processa Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Processa Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JPMorgan Claverhouse Investment Trust Plc
LSE:JCH
|
0.020x |
|
Raketech Group Holding
ST:RAKE
|
0.043x |
|
Kioson Komersial Indonesia Tbk PT
JK:KIOS
|
0.000x |
|
RUBIX Resources Ltd
AU:RB6
|
-1.211x |
|
California Software Company Limited
NSE:CALSOFT
|
-0.032x |
|
Ecoslops SA
PA:ALESA
|
0.259x |
|
GIGLIO.COM S.P.A. O.N.
F:5JR0
|
N/A |
|
Safello Group AB
ST:SFL
|
-0.236x |
Annual Cash Flow Conversion Efficiency for Processa Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Processa Pharmaceuticals Inc from 2011 to 2025. View PCSA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.58 Million | $-11.39 Million | -2.041x | +69.21% |
| 2024-12-31 | $1.70 Million | $-11.25 Million | -6.630x | -310.21% |
| 2023-12-31 | $4.99 Million | $-8.06 Million | -1.616x | -25.70% |
| 2022-12-31 | $7.47 Million | $-9.61 Million | -1.286x | -275.88% |
| 2021-12-31 | $25.49 Million | $-8.72 Million | -0.342x | -149.64% |
| 2020-12-31 | $22.94 Million | $-3.14 Million | -0.137x | +60.08% |
| 2019-12-31 | $8.01 Million | $-2.75 Million | -0.343x | +10.20% |
| 2018-12-31 | $9.70 Million | $-3.71 Million | -0.382x | +91.38% |
| 2017-12-31 | $373.16K | $-1.65 Million | -4.434x | -1106.31% |
| 2016-12-31 | $-1.98 Million | $-871.91K | 0.441x | 0.00% |
| 2015-12-31 | $-1.98 Million | $-871.91K | 0.441x | +119.75% |
| 2014-12-31 | $1.21 Million | $-2.70 Million | -2.231x | -46.86% |
| 2013-12-31 | $1.67 Million | $-2.54 Million | -1.519x | -106.37% |
| 2012-12-31 | $2.56 Million | $-1.89 Million | -0.736x | -187.76% |
| 2011-12-31 | $2.78 Million | $-710.00K | -0.256x | -- |
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer ce… Read more